Stevenage-based NeRRe Therapeutics, a clinical-stage company developing orvepitant, a treatment for disabling chronic cough caused by reflex hypersensitivity disorders, has raised £20m in a series B2 financing round.
NeRRe will now continue the clinical development of orvepitant in chronic cough caused by IPF, a rare type of interstitial lung disease.
The financing round involved a syndicate of transatlantic life sciences investors led by Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, OrbiMed and the UK Government’s Future Fund.
Preparation for the start of the Phase 2 trial is underway.
Dr Mary Kerr, chief executive of NeRRe Therapeutics, said: “After demonstrating that orvepitant reduces the burden of chronic cough in one population, we are delighted to have received the financial support to further advance this promising asset for patients suffering from chronic cough associated with IPF.
“I am also pleased to welcome Columbus Venture Partners to the syndicate and would like to thank our existing investors for their continued support of the NeRRe team, and this exciting first in class asset.”